Member Info for CTSFO

That’s what it means! 👏👏👏

Bump

I’m not trying to spread FUD. I’m just very angry, misled, and trying to work out how we get out of this flat spin with both flames out.

I’m wondering, just wondering, that they haven’t seen the impressive results they expected in the most recent cohorts. Only time will tell. Maybe over worrying here. But it data was good, why no interest or support from BP?

Or is it simply an utterly inept BoD. I simply don’t know WTF has happened here. Fingers crossed this is a forced raise because a deal has fallen through. Scientists playing at being high functioning businesses men.

business men employ scientists, not the other way around. al isn’t up to this. and certainly not at £400k+. ******* y o f f y time. just in an orderly way. after aacr?

BV, exactly this. Will what they present rescue them from the humiliation of this placing? Don’t know whether to take the loss and sell tomorrow, or wait for the dust to settle. Has AS been an arrogant @rse dealing with BP? Or simply to effing selfish in his attitude. Or, effing hope not.. the more recent cohorts aren’t good? But it is safety not efficacy data.

I suggested they were just getting on with it in one of my posts. It hasn’t aged well. Very angry, but at myself as much as anyone else. Over believing the ‘hype’ and downplaying the risk of a newish pharma with a CLN. The science seems robust, but it needs up to date news.

Well and truly p155ed off tonight.

Presenting what? The id lanyards to the delegates at registration? I don’t trust a fecking word from that company anymore. Still harping on about the cohort 3 STS patient. What about all the rest???

All I now hope is this raise was required by the auditors or possibly be seen to have the money here and now to progress with P1aA2?

And AACR does have significant news - verified by an independent research facility.

GLA

The ‘f’ has become redundant.

Well now we have a chance to actually buy shares that benefit the company not the MMs…

Oxygen, I see your point, it’s just that Avacta stamped on rumours in the past. The silence now doesn’t fit with previous behaviour. Time will tell.

There’s certainly a disconnect between “the science” and the sp at present. Something is happening behind the scenes. Because I can’t see a reason for radio silence otherwise. If this is just the company treating the market with contempt, it’s going to be a very very interesting AGM this year.

GLA

Though an old paper (1990s) the importance of a high driving concentration of free doxorubicin is highlighted in this paper. A drop in concentration of drug from periphery to core of the cancer. So, hopefully, very high plasma AVA6000 means high TME penetration throughout all of the tumour. An ‘obliterating’ dose. With adjunct therapies focused on additional cytotoxicity or prevention of MDR, or both! Plus the option of an ongoing safe suppression dose.

https://aacrjournals.org/clincancerres/article/5/7/1703/287594/Doxorubicin-Gradients-in-Human-Breast-Cancer

(I’ve posted this before, excuse the repeat)

GLA

But WTF do I know about medicine? 🤔🤫😇

Studies such as this show the need for adjunct therapy along side plain doxorubicin. Sustained higher free doxorubicin within the TME and tumour cells has got to improve efficacy. This plus adjunct therapy may well show “paradigm shifts” in outcomes. We can but hope.

https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(22)00380-1/abstract

Ice, you’re not wrong. Recent posts of mine on the oncology and trial design have been deleted. 🤦🏻‍♂️.

Afternoon Ice, hope all good.

I’ve gone through the slide decks of recent presentations from Avacta. I think I’ve found the answer to your question about the P1aA2 Q2W dosing trial.

Though plain doxorubicin is a licensed first line treatment for STS, it isn’t actually that effective with its present dosing regime. Looking at the slides it appears Avacta have looked at the data from a STS patient receiving AVA6000 and the rest of their data. From this they’ve extrapolated that Q2W dosing is the optimal regime. They want to drive up the doxorubicin level far higher than the present limits imposed by the Q3W dosing regime of plain doxorubicin.

The Q2W trial will establish safety, start assessment of efficacy, and help determine the MTD or RP2D for the P2 trial. It doesn’t appear to be FDA driven. But good reasons to do it. This also touches on Touk’s comments about cleaving rate of free doxorubicin from AVA6000 by FAP.

GLA.

🙏 Thank you.

WTF are they calling it Abacta not Avacta?? Small but important typo.

I think the chart is approaching a holy hot cross bun tea cup inversion. (*other technical analysis is available)